Single Source: Accelerating Medicines Partnership Schizophrenia (AMP SCZ): Data Processing, Analysis, and Coordination Center (DPACC) (U24 Clinical Trial Not Allowed)

The summary for the Single Source: Accelerating Medicines Partnership Schizophrenia (AMP SCZ): Data Processing, Analysis, and Coordination Center (DPACC) (U24 Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Single Source: Accelerating Medicines Partnership Schizophrenia (AMP SCZ): Data Processing, Analysis, and Coordination Center (DPACC) (U24 Clinical Trial Not Allowed): NIMH is announcing its intent to issue a single source cooperative agreement award to Brigham and Women"s Hospital to support continuation of the AMP® SCZ Data Processing, Analysis, and Coordination Center (DPACC). This allows DPACC to complete the processing and analysis of longitudinal multi-modal biomarker and clinical outcome data collected across 24 months.This is a Notice of Funding Opportunity (NOFO) for a Single Source that will invite application(s) from eligible organization(s) to apply. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding.

Federal Grant Title:	Single Source: Accelerating Medicines Partnership Schizophrenia (AMP SCZ): Data Processing, Analysis, and Coordination Center (DPACC) (U24 Clinical Trial Not Allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-MH-27-205
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.242
CFDA Descriptions:	Information not provided
Current Application Deadline:	June 9th, 2026
Original Application Deadline:	June 9th, 2026
Posted Date:	May 7th, 2026
Creation Date:	May 7th, 2026
Archive Date:	August 8th, 2026
Total Program Funding:	$5,000,000
Maximum Federal Grant Award:	$5,000,000
Minimum Federal Grant Award:
Expected Number of Awards:	1
Cost Sharing or Matching:	No
Last Updated:	May 7th, 2026

Applicants Eligible for this Grant: Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Eligible Organizations:Only the Brigham and Women's Hospital may apply for this single source NOFO.Only the following applicant is eligible to apply for this single source funding: Brigham and Women"s Hospital. Please refer to Section I. Notice of Funding Opportunity Information for more details.Foreign Organizations/Foreign Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Grant Announcement Contact: National Institute of Mental Health (NIMH)
[email protected]
[email protected]
Similar Government Grants: • Advancing Research on Empirically-Supported Interventions for Older Adults Living with Ser...; • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...; • Using Archived Data and Specimen Collections to Advance Maternal and Pediatric HIV/AIDS Re...; • Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowe...; • Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Int...; • Development of Biomarkers for Mental Health Research and Clinical Utilities: (STTR [R41/R4...; • Development of Biomarkers for Mental Health Research and Clinical Utilities (SBIR [R43/R44...; • Pharmacologic Agents and Drugs for Mental Disorders (SBIR [R43/R44])
More Grants from the National Institutes of Health: • Science Track Award for Research Transition (START) Program (R03, Clinical Trial Optional); • Avant Garde/Avenir Awards for Investigators Conducting High Risk/High Reward Research on H...; • NIH Research Educational Program - Mentoring Activities & Networks (Parent R25/UE5 - Clini...; • NIH Research Education Program - Research Experiences (Parent R25 - Clinical Trial Not All...; • Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Ad...